Document Detail


Biological Agents in the Management of Felty's Syndrome: A Systematic Review.
MedLine Citation:
PMID:  22119104     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: To review and summarize the information available on the effectiveness and safety of biological therapies in refractory Felty's syndrome (FS). METHODS: We describe a case of FS with severe neutropenia and recurrent bacterial infections unresponsive to disease-modifying antirheumatic drug treatment and long-term administration with granulocyte colony-stimulating factor, in which treatment with rituximab (RTX) was useful and resulted in a sustained neutrophil response. Current evidence on the use of biological therapies in FS is also analyzed through a systematic review of the English-language literature, based on a PubMed search. RESULTS: Available data on the use of biological therapies in refractory FS are based only on several case reports and are limited to the use of RTX and some anti-tumor necrosis factor α agents (etanercept, infliximab, and adalimumab). Including the case described here, data are available on 8 patients treated with RTX. A sustained increase in the absolute neutrophil count (>1500/mm(3)) was observed in 62.5% (5/8) of these patients after 1 cycle of treatment. In most of them, the hematological response was accompanied by a parallel improvement in biological markers of inflammation and other clinical manifestations of FS (arthritis, recurrent infections, systemic symptoms, etc). After a median follow-up of 9 months (range, 6-14), only 1 of these patients relapsed and neutropenia reappeared; in this patient, retreatment was rapidly effective. No significant adverse events related to RTX therapy were reported. Experience with anti-tumor necrosis factor agents is limited to 6 patients, none of whom presented any sustained increase in neutrophil count. CONCLUSIONS: Although it is not yet possible to make definite recommendations, the global analysis of all cases reported to date only supports the use of RTX as a second-line therapy in patients with refractory FS.
Authors:
Javier Narváez; Eva Domingo-Domenech; Carmen Gómez-Vaquero; Laura López-Vives; Paula Estrada; María Aparicio; Irene Martín-Esteve; Joan Miquel Nolla
Related Documents :
10949804 - Necrotizing fasciitis in the lower extremity: a review and case presentation.
9030164 - Total external and internal construction in arhinia.
22225674 - 'animal-type' melanoma of the scalp with satellitosis and positive sentinel nodes in a ...
9109994 - Thoracic intraspinal paracoccidioidomycosis. case report.
959074 - Allergic alveolar diseases. problems in diagnosis and management.
22346174 - Solitary median maxillary central incisor in association with hemifacial microsomia: a ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-11-23
Journal Detail:
Title:  Seminars in arthritis and rheumatism     Volume:  -     ISSN:  1532-866X     ISO Abbreviation:  -     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1306053     Medline TA:  Semin Arthritis Rheum     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Affiliation:
Department of Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell art...
Next Document:  Natural course of epilepsy concomitant with CNS tuberculomas.